All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
The abstract shows that mitazalimab effectively enhances the effects of chemotherapy, especially with FOLFIRINOX, leading to improved long-term survival in a preclinical tumor model.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CAN04,Leucovorin,Fluorouracil
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
Clinical trial application has been submitted for a study which investigates CAN04 in combination with FOLFIRINOX treatment, one of the two most commonly used first line chemotherapies in PDAC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2020
Details:
The upcoming Phase II study OPTIMIZE-1 is an open-label, multicenter study evaluating the clinical effect of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with advanced pancreatic cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naptumomab estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: ABR-217620
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: NeoTX Therapeutics
Deal Size: $71.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 11, 2020
Details:
In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
Details:
Recently, new benchmark data was published showing that mitazalimab has the potential to be best-in-class in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1015
Therapeutic Area: Oncology Product Name: ATOR-1015
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The presentations include the phase I study with ATOR-1015, the project ALG-APV-527 which is being developed in collaboration with Aptevo Therapeutics and is ready for clinical phase I studies, and the new bispecific concept Neo-X-Prime.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATOR-1017
Therapeutic Area: Oncology Product Name: ATOR-1017
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
The Data Review Committee, which monitors the safety of patients in the Phase I study with ATOR-1017, has approved the dose of 100 mg and granted the start of dosing with 200 mg, corresponding to approximately 3.2 mg / kg.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DS-1055
Therapeutic Area: Oncology Product Name: DS-1055
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 22, 2020
Details:
BioInvent has received the millstone payment in connection to the initiation of a global Phase I clinical trial with an anti-glycoprotein A repetitions predominant (GARP) directed antibody. The antibody DS-1055 was discovered by Daiichi Sankyo and targets GARP.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitazalimab
Therapeutic Area: Oncology Product Name: ADC-1013
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
The results from the study show that a large number of genes are upregulated after treatment with mitazalimab, for example PD-L1, which supports the clinical development plan for mitazalimab which includes combination studies with PD-1 inhibitors.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
